Annovis Bio (FRA:07X) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:07X Annovis Bio Inc FRA:07X
39 GF Score
Price €1.50
! 1 Warning Sign
View Full Analysis

What is Annovis Bio FFO per Share?

FFO per Share only applies to REITs.

FRA:07X
39GF Score
Annovis Bio Inc FRA:07X
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Annovis Bio Business Description

Other Exchanges ANVS:USA
Address 101 Lindenwood Drive, Suite 225, Malvern, PA, USA, 19355
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
39GF Score

Get the complete analysis for FRA:07X

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.50
Price